Abstract:Metabolic reprogramming occurs in tumors to foster cancer cell proliferation, survival and metastasis, but as well at a systemic level affecting the whole organism, eventually leading to cancer cachexia. Indeed, as cancer cells rely on external sources of nitrogen and carbon skeleton to grow, systemic metabolic deregulation promoting tissue wasting and metabolites mobilization ultimately supports tumor growth. Cachectic patients experience a wide range of symptoms affecting several organ functions such as muscle, liver, brain, immune system and heart, collectively decreasing patients’ quality of life and worsening their prognosis. Moreover, cachexia is estimated to be the direct cause of at least 20% of cancer deaths. The main aspect of cachexia syndrome is the unstoppable skeletal muscle and fat storage wasting, even with an adequate caloric intake, resulting in nutrient mobilization – both directly as lipid and amino acids and indirectly as glucose derived from the exploitation of liver gluconeogenesis – that reaches the tumor through the bloodstream. From a metabolic standpoint, cachectic host develops a wide range of dysfunctions, from increased insulin and IGF-1 resistance to induction of mitochondrial uncoupling proteins and fat tissue browning resulting in an increased energy expenditure and heat generation, even at rest. For a long time, cachexia has been merely considered an epiphenomenon of end-stage tumors. However, in specific tumor types, such as pancreatic cancers, it is now clear that patients present markers of tissue wasting at a stage in which tumor is not yet clinically detectable, and that host amino acid supply is required for tumor growth. Indeed, tumor cells actively promote tissue wasting by secreting specific factors such as parathyroid hormone-related protein and micro RNAs. Understanding the molecular and metabolic mediators of cachexia will not only advance therapeutic approaches against cancer, but also improve patients’ quality of life.

[Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions]

Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment

The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations

Addressing cancer anorexia-cachexia in older patients: potential therapeutic strategies and molecular pathways

Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management

Understanding cachexia as a cancer metabolism syndrome

Bridging gaps in cancer cachexia Care: Current insights and future perspectives

The cachexia clinic: from staging to managing nutritional and functional problems in advanced cancer patients

Pancreatic Cancer Cachexia: The Role of Nutritional Interventions

Cancer cachexia：pathogenic mechanisms and therapeutic perspectives

The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer

Molecular Mechanisms of Cachexia: A Review

IUPHAR ECR review: Cancer-related anorexia-cachexia in cancer patients: Pathophysiology and treatment

Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia

[Nutritional supportive care in the course of patients with esophagogastric cancers]

Amino Acids in Cancer and Cachexia: An Integrated View

Treatment of Cachexia in Gastric Cancer: Exploring the Use of Anti-Inflammatory Natural Products and Their Derivatives

A multimodal approach to cancer-related cachexia: from theory to practice

Cancer Cachexia: Molecular Mechanism and Pharmacological Management

Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions

Molecular mechanisms of cancer cachexia‐induced muscle atrophy (Review)